scholarly journals Findings and Graduation of Sarcoidosis-Related Uveitis: A Single-Center Study

Cells ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 89
Author(s):  
Lynn S. zur Bonsen ◽  
Dominika Pohlmann ◽  
Anne Rübsam ◽  
Uwe Pleyer
Keyword(s):  
International Workshop ◽  
Interleukin 2 ◽  
Ocular Involvement ◽  
Laboratory Findings ◽  
Ocular Sarcoidosis ◽  
Single Center Study ◽  
Study Population ◽  
Chest X Ray ◽  
Soluble Interleukin 2 Receptor

Ocular involvement is present in up to 79% of sarcoid patients. Uveitis is the main ocular manifestation and presents as a chronic intraocular inflammatory condition with potentially detrimental effects on visual acuity and quality of life. This retrospective study was conducted to explore the incidence and characteristics of ocular sarcoidosis in a single tertiary ophthalmology center. Medical records of 84 patients presenting between June 2007 and March 2021 were analyzed. Based on the “International Workshop on Ocular Sarcoidosis” (IWOS) criteria, ocular sarcoidosis was determined as: definite (n = 24; 28.6%), presumed (n = 33; 39.3%), probable (n = 10; 11.9%), and indefinite (n = 17; 20.2%) in our study population. In 43.9% of the definite and presumed cases, the eye was primarily affected. In addition to specific ocular findings, the diagnosis was supported by biopsy (28.6%) and chest x-ray or computer tomography (66.7%). Moreover, an increased soluble interleukin-2 receptor (sIL-2R) expression (76.2%), elevated angiotensin-converting enzyme (ACE) levels (34.8%), and lymphocytopenia (35.1%) were valuable laboratory findings. Co-affected organs were lungs (60.7%), skin (15.5%), and central nervous system (8.3%). Our findings support the prominent role of the eye in the early detection of sarcoidosis. In addition to the IWOS criteria, sIL-2R, in particular, was shown to be relevant in establishing the diagnosis.

scholarly journals FP125A ROLE OF SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN THE PREDICTION OF STEROID RESPONSE IN PATIENTS WITH TUBULOINTERSTITIAL NEPHRITIS

2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Satoka Shiratori ◽  
Daigo Nakazawa ◽  
Jyunpei Yoshikawa ◽  
Takashi Kudo ◽  
Kanako Kusunoki ◽  
...  
Keyword(s):  
Tubulointerstitial Nephritis ◽  
Interleukin 2 ◽  
Steroid Response ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy: Results of 2 consecutive studies in a single referral institution.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 10539-10539
Author(s):  
Jaume Mora ◽  
Alicia Castañeda ◽  
Miguel Angel Flores ◽  
Vicente Santa-María ◽  
Moira Garraus ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Cooperative Groups ◽  
Gm Csf ◽  
Stem Cell Rescue ◽  
Single Center Study ◽  
Study Population

10539 Background: Treatment of high-risk NB within the major international cooperative groups (COG and SIOP) comprise intensive induction, consolidation with high dose chemotherapy and autologous stem cell rescue (ASCR) followed by anti-GD2 immunotherapy and isotretinoin as maintenance therapy. In the COG studies dinutuximab and cytokines (GM-CSF and IL-2) were used to treat patients in complete remission (CR) after ASCR whereas SIOPEN studies used dinutuximab-beta plus/minus IL-2 and included patients with responsive (no progression 109 days after ASCR) but refractory (skeletal metaiodobenzylguanidine positivity with three or fewer areas of abnormal uptake). Methods: Since December 2014, HR-NB patients referred to HSJD were eligible for consolidation with anti-GD2/GM-CSF immunotherapy in 2 consecutive studies (dinutuximab for EudraCT 2013-004864-69 and naxitamab for 017-001829-40) and naxitamab/GM-CSF compassionate use (CU) with or without prior ASCR. Patients were enrolled in 1st CR or with primary refractory bone/bone marrow (B/BM) disease. We accrued a study population of two groups whose consolidative therapy, aside from ASCR, was similar: anti-GD2 (dinutuximab or naxitamab) antibodies + GM-CSF and local radiotherapy. This is a retrospective analysis of their event-free survival (EFS) and overall survival (OS) calculated from study entry. Results: From Dec 14 til Dec 19, 67 study patients were treated with the COG (dinutuximab + GM-CSF+ IL-2 + RA) regimen (n = 21) in the HSJD-HRNB-Ch14.18 study or with Naxitamab and GM-CSF in the Ymabs study 201 (n = 12) or CU (n = 34). 23 patients were treated with primary refractory disease in the B/BM, and 44 in 1st CR. The 67 study patients included 13 (19%) treated following single ASCR and 54 following induction chemotherapy and surgery. Median follow-up for all surviving patients is 16.2 months. Two-year rates for ASCR and non-ASCR patients were, respectively: EFS 64% vs. 54% (p = 0.28), and OS 66.7% vs. 84% (p = 0.8). For the 44 pts in 1st CR, 2-year rates for ASCR and non-ASCR patients were, respectively: EFS 65% vs. 58% (p = 0.48), and OS 71% vs. 85% (p = 0.63). Conclusions: In this retrospective, single center study, ASCR did not provide survival benefit when anti-GD2 + GM-CSF based immunotherapy was used for consolidation after dose-intensive conventional chemotherapy.

Increased Level of Soluble Interleukin-2 Receptor in Advanced Solid Tumors: A Preliminary Study

1988 ◽  
Vol 74 (6) ◽  
pp. 633-637 ◽  
Author(s):  
Franco Rovelli ◽  
Paolo Lissoni ◽  
Sergio Crispino ◽  
Sandro Barni ◽  
Gabriele Fumagalli ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Solid Tumors ◽  
Interleukin 2 ◽  
Normal Subjects ◽  
Serum Levels ◽  
High Serum ◽  
Human Solid Tumors ◽  
Soluble Interleukin 2 Receptor ◽  
Preliminary Study

Both activated normal and transformed lymphocytes produce not only cell-associated but also cell-free IL-2R. Evidence of high serum concentrations of IL-2R appears to serve as a tumor marker in patients with lymphomas On the contrary, the role of soluble IL-2R in solid neoplasms has still to be defined. This investigation was carried out to analyze soluble IL-2R production in human solid tumors. The study included 35 patients with solid tumors (12 without and 23 with metastases), 58 healthy subjects and 6 lymphoma patients. Among cancer patients, lung and breast carcinoma were the two most frequent neoplasms. In each subject or patient, serum levels of IL-2R were measured by using an enzyme immunoassay. Moreover, in 14/23 patients with metastatic solid tumors, lymphocyte subpopulations were also evaluated. Serum levels of IL-2R were significantly higher in the cancer patients than in the normal subjects. The patients with metastatic solid tumors showed significantly higher mean levels than those without metastases, and similar to those observed in the lymphoma patients. Finally, there was no correlation between serum levels of IL-2R and the T4/T8 ratio, which was reduced in 5/14 cancer patients. Further studies will be needed to establish if elevated concentrations of IL-2R in the serum can contribute to the immunoincompetence of patients with disseminated solid neoplasms.

Role of Soluble Interleukin-2 Receptor Levels in Patients with Latent Tuberculosis

Lung ◽  
2006 ◽  
Vol 184 (1) ◽  
pp. 21-24 ◽  
Author(s):  
David Shitrit ◽  
Gabriel Izbicki ◽  
Ariella Bar-Gil Shitrit ◽  
Meir Raz ◽  
Jaquline Sulkes ◽  
...  
Keyword(s):  
Interleukin 2 ◽  
Latent Tuberculosis ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

scholarly journals The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies

2020 ◽  
Vol 11 ◽  
Author(s):  
Jaume Mora ◽  
Alicia Castañeda ◽  
Miguel A. Flores ◽  
Vicente Santa-María ◽  
Moira Garraus ◽  
...  
Keyword(s):  
Stem Cell ◽  
Complete Remission ◽  
Stem Cell Transplant ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Conventional Chemotherapy ◽  
Single Center Study ◽  
Study Population

Background: Treatment of HR-NB comprise induction, consolidation with autologous stem cell transplant (ASCT) followed by anti-GD2 immunotherapy and isotretinoin. Childrens Oncology Group and SIOPEN studies used dinutuximab and cytokines to treat patients in complete remission or refractory Bone/Bone marrow (B/BM) disease after ASCT.Methods: HR-NB patients referred to Hospital Sant Joan de Déu for anti-GD2 immunotherapy were eligible for two consecutive studies (dinutuximab for EudraCT 2013–004864–69 and naxitamab for 017–001829–40) and naxitamab/Sargramostim CU with or without prior ASCT. Patients enrolled in first complete remission or with primary refractory B/BM disease. We accrued a study population of two groups whose therapy, aside from ASCT, was similar. This is a retrospective analysis of their outcome calculated from study entry.Results: From December 2014–2019, 67 patients were treated with dinutuximab and cytokines (n = 21) in the Hospital Sant Joan de Déu-HRNB-Ch14.18 study or with naxitamab and Sargramostim either in the Ymabs study 201 (n = 12) or CU (n = 34). 23 patients were treated with primary refractory disease in the B/BM (11 with dinutuximab and 12 with naxitamab), and 44 in first CR (10 with dinutuximab and 34 with naxitamab). Study patients included 13 (19.4%) treated following single ASCT and 54 following conventional chemotherapy. Median follow-up for all patients is 16.2 months. Two-year rates for ASCT and non-ASCT patients were, respectively, EFS 64.1% vs. 54.2% (p = 0.28), and OS 66.7% vs. 84.1% (p = 0.81). For the 44 pts in first CR, 2-years rates for ASCT and non-ASCT patients were, respectively, EFS 65.5% vs. 58.7% (p = 0.48), and OS 71.4% vs. 85.4% (p = 0.63).Conclusions: In this retrospective, single center study, ASCT did not provide survival benefit when anti-GD2 immunotherapy was used after induction chemotherapy.

scholarly journals THE ROLE OF SERUM SOLUBLE INTERLEUKIN 2 RECEPTOR (sIL-2R) LEVELS IN PATIENTS WITH RENAL CELL CARCINOMA

1997 ◽  
Vol 88 (4) ◽  
pp. 473-478
Author(s):  
Kin-ya Akiyama ◽  
Masahito Tsuji ◽  
Yasushi Kurokawa ◽  
Kin-ya Yokota ◽  
Keiji Kojima ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor
Sign in / Sign up

Export Citation Format

Share Document